Abstract:

Objective To explore the influence of xeroderma pigmentosum group C（XPC）genetic variation on the prognosis and safety of stage Ⅲ patients with colorectal cancer（CRC）receiving oxaliplatin⁃based adjuvant chemotherapy. Methods A total of 186 patients with CRC who were treated with surgical resection and oxaliplatin⁃ based adjuvant chemotherapy were included in this study. Peripheral blood specimens of the patients were collected for genetic variation analysis of XPC gene. The univariate analysis between XPC genetic variation and prognosis was performed by Kaplan⁃Meier survival analysis. The correlation analysis between genotype and adverse reactions was analyzed using chi⁃square test. Results The median disease⁃free survival（DFS）and overall survival（OS） of the 186 patients with CRC was 4.3 years and 5.5 years，respectively. Rs2228001 was of clinical significance with prognosis and safety. Prognostic analysis demonstrated that the median DFS of patients with TT genotype and TG/GG genotype was 3.8 and 5.0 years respectively ，which was statistically significant（P = 0.012）. Fur⁃ thermore，the median OS of the two genotypes were 5.0 and 5.7 years respectively，which was marginal statistical significance（P = 0.021）. The association analysis between rs2228001 genotype and adverse reaction suggested that patients with TG/GG genotype were associated with a relatively higher incidence of neurotoxicity than that with TT genotype（72.9% vs. 55.4% ，P = 0.014）. Conclusion XCP gene rs2228001 polymorphism could be used as a biomarker for prognosis and neurotoxicity evaluation of patients with CRC who received oxaliplatin⁃based adjuvant chemotherapy. 

Key words:

colorectal cancer, xeroderma pigmentosum group C, genetic variation, prognosis, safety, biomarker